Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer

Adjuvant chemoradiotherapy improved survival outcomes vs pelvic radiotherapy alone in patients with high-risk endometrial cancer, with the most clinically relevant benefit observed in those with p53 abnormalities, according to preplanned…

Continue Reading